Wegovy HD: What the FDA’s 7.2 mg Semaglutide Approval Means—and What It Does Not

Updated 14 September 2026. On 19 March 2026, the US Food and Drug Administration approved Wegovy HD, a 7.2 mg semaglutide injection, for weight reduction and long-term weight maintenance in certain adults with obesity or overweight with a weight-related condition.

What changed

The decision adds a higher-dose presentation to the US Wegovy label. The FDA said supporting clinical data showed additional average weight reduction compared with previously approved doses, with a safety profile broadly consistent with known semaglutide effects.

Safety context in the FDA notice

The agency listed gastrointestinal effects—including nausea, vomiting, diarrhoea, constipation and abdominal pain—as the most common adverse reactions. Altered skin sensation was also reported more often at the higher dose, and the FDA said it was investigating that reaction further. The existing boxed warning concerning thyroid C-cell tumours remains part of the US labelling.

What the approval does not mean

• It does not establish that a higher dose is appropriate for every person.
• It does not make unapproved semaglutide products equivalent to the regulated medicine.
• It is a US approval, not an Australian ARTG decision.
• It does not erase the need to examine the full label, study design, discontinuations and adverse-event tables.

Why jurisdiction matters

Regulatory status is country-specific. Australian readers should verify current inclusion and indications through the TGA and ARTG rather than importing a US claim. A molecule, brand, strength and indication can each have a different status.

Primary source

FDA approval announcement, 19 March 2026. Read alongside our Australian regulatory guide and FDA unapproved GLP-1 warning analysis.

General scientific information only; not medical advice.